REG - Ondine Biomedical - Issue of Equity and TVR

Ondine BiomedicalAnnouncement

21/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230821:nRSU8413Ja&default-theme=true

RNS Number : 8413J  Ondine Biomedical Inc.  21 August 2023

21 August 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Issue of Equity & Total Voting Rights

Ondine Biomedical Inc. (AIM: OBI) announces the issue of 78,719 common shares
in the Company ("Common Shares") pursuant to an annual bonus award for a staff
member. The Common Shares are being issued at a price of $0.212 USD* per
Common Share.

 

Admission and Total Voting Rights

Application is being made for the admission to trading on AIM ("Admission") of
the 78,719 Common Shares, which will rank pari passu in all respects with the
Company's existing common shares. Admission of the Common Shares is expected
to become effective on 23 August 2023.

Following Admission, the total number of Common Shares in the Company with
voting rights will be 195,062,126. The Company does not hold any shares in
Treasury. The above figure of 195,062,126 Common Shares may be used by
shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company.

* Based on the Company's closing share price, and GBP/USD exchange rate, on 27
March 2023 being the reference date for the bonus award.

 Ondine Biomedical Inc.
 Angelika Vance, Corporate Communications                                                                    +001 (1) 604 838 2702

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam                                                                             +44 (0)20 7496 3000
 Butcher

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                                                                              +44 (0) 20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                                                                            +44 (0) 77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Ondine's nasal photodisinfection technology is approved
in several jurisdictions under the brand name Steriwave™. It has been
awarded the CE mark and, in the US, has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPMPTMTJBBRJ